Results 241 to 250 of about 1,237,541 (256)
Some of the next articles are maybe not open access.
ISIS-3521. Isis Pharmaceuticals.
Current opinion in investigational drugs (London, England : 2000), 2002ISIS-3521 is a 20-mer antisense phosphorothioate oligonucleotide PKCa expression inhibitor, under development by Isis (formerly in collaboration with Novartis) for the potential treatment of solid tumors that are refractory to, or recurrent with, standard treatment regimens [175741].
K, Li, J, Zhang
openaire +1 more source
Proceedings of the 1985 ACM SIGMOD international conference on Management of data, 1985
ISIS IS an experimental system for graphically manlpulatmg a database The system 1s based on a simply specified high-level semantic data model It demonstrates the capablbtles of a workstation environment by mtegratmg three aspects of database programming m one graphical setting Namely, it permits database constructlon and modification, it allows ...
Kenneth J. Goldman +3 more
openaire +1 more source
ISIS IS an experimental system for graphically manlpulatmg a database The system 1s based on a simply specified high-level semantic data model It demonstrates the capablbtles of a workstation environment by mtegratmg three aspects of database programming m one graphical setting Namely, it permits database constructlon and modification, it allows ...
Kenneth J. Goldman +3 more
openaire +1 more source
ISIS-14803 (Isis Pharmaceuticals).
Current opinion in investigational drugs (London, England : 2000), 2002Isis and Merck are developing an antisense oligonucleotide for the potential treatment of hepatitis C virus (HCV) infection [305306]. As of March 2000, the lead from this program, ISI-14803, was being studied in a phase I/II trial where it was administered in three weekly 2-h infusions for 4 weeks [327913], [357823].
openaire +1 more source
Technology evaluation: ISIS-113715, Isis.
Current opinion in molecular therapeutics, 2005Isis is developing ISIS-113715, an antisense inhibitor of the PTP1B gene, for the potential treatment of type 2 diabetes and obesity. ISIS-113715 is undergoing phase II clinical trials.
openaire +1 more source